{"id":26598,"date":"2022-09-09T08:00:29","date_gmt":"2022-09-09T07:00:29","guid":{"rendered":"https:\/\/cannabishealthnews.co.uk\/?p=26598"},"modified":"2022-09-09T09:17:05","modified_gmt":"2022-09-09T08:17:05","slug":"finding-the-right-balance-the-benefits-of-mixing-thc-and-cbd-flower-zerenia","status":"publish","type":"post","link":"https:\/\/cannabishealthnews.co.uk\/2022\/09\/09\/finding-the-right-balance-the-benefits-of-mixing-thc-and-cbd-flower-zerenia\/","title":{"rendered":"Finding the right balance: the benefits of mixing THC and CBD flower"},"content":{"rendered":"
The shifting regulatory, legal, and cultural landscape surrounding cannabis use for medicinal purposes in the UK has led to increased concerns regarding the risks that high-potency cannabis consumption poses to public health. <\/span><\/p>\n A recent systematic review published in <\/span>the Lancet Psychiatry<\/i><\/b><\/a> by researchers from the Addiction and Mental Health Group at the University of Bath suggests that use of THC-predominant cannabis is associated with an increased risk of experiencing psychosis and cannabis use disorder (CUD) compared to low-THC cannabis chemotypes. <\/span><\/p>\n The review, which included 20 studies with a total of 119,581 participants, noted that high-potency users were more likely to experience problems related to their cannabis use while low-potency product users did not appear to be at an increased risk compared to non-users. For anxiety,<\/a> study findings were more mixed, and all but one of the studies on depression found no association with high-THC products.<\/span><\/p>\n Lead authors Kat Petrilli and Tom Freeman said in <\/span>a statement<\/b><\/a>: \u201cOur findings suggest that people who use cannabis could reduce their risk of harm by using lower potency products. These results are important in the context of harm reduction which aims to minimise the negative consequences associated with high-THC cannabis use.\u201d<\/span><\/p>\n